The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911

Latest Cancer News

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (02-26-2015)

The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment of people with PD-L1 (Programmed Death-Ligand... Continue Reading

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (02-25-2015)

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens,... Continue Reading

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia (02-24-2015)

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (02-23-2015)

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (02-20-2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer (02-19-2015)

The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According to... Continue Reading

Intravenous Administration of Erwinaze® Approved by FDA (02-18-2015)

The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi).  Erwinaze is utilized as a component of a multi-agent chemotherapeutic regimen for the treatment of patients... Continue Reading

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera (02-17-2015)

A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (02-12-2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (02-11-2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported... Continue Reading

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC (02-10-2015)

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However the... Continue Reading

New Research Concludes that Majority of Cancers Are “Bad Luck”—or Random Mutations (02-9-2015)

According to recent research, the majority of cancers are caused by random mutations in cell DNA during stem cell division, as opposed to lifestyle, inherited, or environmental risk factors. These findings were reported in the journal Science. It’s... Continue Reading

Next Page »